Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Chromosomal imbalances in human bladder urothelial carcinoma: similarities and differences between biopsy samples and cancer stem-like cells

Authors: Donatella Conconi, Elena Panzeri, Serena Redaelli, Giorgio Bovo, Paolo Viganò, Guido Strada, Leda Dalprà, Angela Bentivegna

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The existence of two distinct groups of tumors with different clinical characteristic is a remarkable feature of transitional cell carcinomas (TCCs) of the bladder. More than 70% are low-grade (LG) non-infiltrating (NI) cancers at diagnosis, but 60-80% of them recur at least one time and 10-20% progress in stage and grade. On the other hand, about 20% of tumors show muscle invasion (IN) and have a poor prognosis with <50% survival after 5 years. This study focuses on the complexity of the bladder cancer genome, and for the first time to our knowledge, on the possibility to compare genomic alterations of in vitro selected cancer stem-like cells (CSCs), and their original biopsy in order to identify different genomic signature already present in the early stages of tumorigenesis of LG and HG tumors.

Methods

We initially used conventional chromosome analysis on TCC biopsies with different histotypes (LG vs HG) in order to detect rough differences between them. Then, we performed array comparative genomic hybridization (aCGH) on 10 HG and 10 LG tumors providing an overview of copy number alterations (CNAs). Finally, we made a comparison of the overall CNAs in 16 biopsies and their respective CSCs isolated from them.

Results

Our findings indicate that LG and HG bladder cancer differ with regard to their genomic profile even in the early stage of tumorigenesis; moreover, we identified a subgroup of LG samples with a higher tendency to lose genomic regions which could represent a more aggressive phenotype.

Conclusions

The outcomes not only provide valuable information to deeper studying TCC carcinogenesis, but also could help in the clinic for diagnosis and prognosis of patients who will benefit from a more aggressive therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kawanishi H, Takahashi T, Ito M, Matsui Y, Watanabe J, Ito N, Kamoto T, Kadowaki T, Tsujimoto G, Imoto I, Inazawa J, Nishiyama H, Ogawa O: Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. Br J Cancer. 2007, 97 (2): 260-266. 10.1038/sj.bjc.6603850.CrossRefPubMedPubMedCentral Kawanishi H, Takahashi T, Ito M, Matsui Y, Watanabe J, Ito N, Kamoto T, Kadowaki T, Tsujimoto G, Imoto I, Inazawa J, Nishiyama H, Ogawa O: Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. Br J Cancer. 2007, 97 (2): 260-266. 10.1038/sj.bjc.6603850.CrossRefPubMedPubMedCentral
2.
go back to reference Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005, 5 (9): 713-725. 10.1038/nrc1697.CrossRefPubMed Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005, 5 (9): 713-725. 10.1038/nrc1697.CrossRefPubMed
3.
go back to reference Goebell PJ, Knowles MA: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010, 28 (4): 409-428. 10.1016/j.urolonc.2010.04.003.CrossRefPubMed Goebell PJ, Knowles MA: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010, 28 (4): 409-428. 10.1016/j.urolonc.2010.04.003.CrossRefPubMed
4.
go back to reference Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, de Gil Diez Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001, 158 (6): 1955-1959. 10.1016/S0002-9440(10)64665-2.CrossRefPubMedPubMedCentral Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, de Gil Diez Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001, 158 (6): 1955-1959. 10.1016/S0002-9440(10)64665-2.CrossRefPubMedPubMedCentral
5.
go back to reference Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003, 63 (23): 8108-8112.PubMed Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003, 63 (23): 8108-8112.PubMed
6.
go back to reference Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst. 1992, 84 (16): 1251-1256. 10.1093/jnci/84.16.1251.CrossRefPubMed Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst. 1992, 84 (16): 1251-1256. 10.1093/jnci/84.16.1251.CrossRefPubMed
7.
go back to reference Proctor AJ, Coombs LM, Cairns JP, Knowles MA: Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991, 6 (5): 789-795.PubMed Proctor AJ, Coombs LM, Cairns JP, Knowles MA: Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene. 1991, 6 (5): 789-795.PubMed
8.
go back to reference Bringuier PP, Tamimi Y, Schuuring E, Schalken J: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996, 12 (8): 1747-1753.PubMed Bringuier PP, Tamimi Y, Schuuring E, Schalken J: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996, 12 (8): 1747-1753.PubMed
9.
go back to reference Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991, 63 (4): 601-608. 10.1038/bjc.1991.139.CrossRefPubMedPubMedCentral Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991, 63 (4): 601-608. 10.1038/bjc.1991.139.CrossRefPubMedPubMedCentral
10.
go back to reference Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G: Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 2002, 21 (16): 2476-2483. 10.1038/sj.onc.1205304.CrossRefPubMed Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G: Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 2002, 21 (16): 2476-2483. 10.1038/sj.onc.1205304.CrossRefPubMed
11.
go back to reference Bruch J, Schulz WA, Häussler J, Melzner I, Brüderlein S, Möller P, Kemmerling R, Vogel W, Hameister H: Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res. 2000, 60 (16): 4526-4530.PubMed Bruch J, Schulz WA, Häussler J, Melzner I, Brüderlein S, Möller P, Kemmerling R, Vogel W, Hameister H: Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res. 2000, 60 (16): 4526-4530.PubMed
12.
go back to reference Knowles MA: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int. 1999, 84 (4): 412-427.CrossRefPubMed Knowles MA: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int. 1999, 84 (4): 412-427.CrossRefPubMed
13.
go back to reference Nascimento e Pontes MG, da Silveira SM, Trindade Filho JC, Rogatto SR, de Viana Camargo JL: Chromosomal imbalances in successive moments of human bladder urothelial carcinoma. Urol Oncol. 2013, 31 (6): 827-835. 10.1016/j.urolonc.2011.05.015.CrossRefPubMed Nascimento e Pontes MG, da Silveira SM, Trindade Filho JC, Rogatto SR, de Viana Camargo JL: Chromosomal imbalances in successive moments of human bladder urothelial carcinoma. Urol Oncol. 2013, 31 (6): 827-835. 10.1016/j.urolonc.2011.05.015.CrossRefPubMed
14.
go back to reference Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, Guo Y, McDougal WS, Kwiatkowski DJ: Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One. 2013, 8 (4): e60927-10.1371/journal.pone.0060927.CrossRefPubMedPubMedCentral Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, Guo Y, McDougal WS, Kwiatkowski DJ: Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One. 2013, 8 (4): e60927-10.1371/journal.pone.0060927.CrossRefPubMedPubMedCentral
15.
go back to reference Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM: Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005, 11 (19 Pt 1): 7012-7022.CrossRefPubMed Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM: Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005, 11 (19 Pt 1): 7012-7022.CrossRefPubMed
16.
go back to reference Shen H, Morrison CD, Zhang J, Underwood W, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, Liu S, Trump DL, Candace JS: 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013, 4 (11): 2124-2134.CrossRefPubMedPubMedCentral Shen H, Morrison CD, Zhang J, Underwood W, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, Liu S, Trump DL, Candace JS: 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013, 4 (11): 2124-2134.CrossRefPubMedPubMedCentral
17.
go back to reference Nord H, Segersten U, Sandgren J, Wester K, Busch C, Menzel U, Komorowski J, Dumanski JP, Malmström PU, de Díaz Ståhl T: Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer. 2010, 126 (6): 1390-1402.PubMed Nord H, Segersten U, Sandgren J, Wester K, Busch C, Menzel U, Komorowski J, Dumanski JP, Malmström PU, de Díaz Ståhl T: Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer. 2010, 126 (6): 1390-1402.PubMed
18.
go back to reference Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L, Weissman IL: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009, 106 (33): 14016-14021. 10.1073/pnas.0906549106.CrossRefPubMedPubMedCentral Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L, Weissman IL: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009, 106 (33): 14016-14021. 10.1073/pnas.0906549106.CrossRefPubMedPubMedCentral
19.
go back to reference Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, Xu KW, Huang H, Yin XB, Huang J: Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res. 2009, 37 (3): 621-630. 10.1177/147323000903700304.CrossRefPubMed Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, Xu KW, Huang H, Yin XB, Huang J: Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res. 2009, 37 (3): 621-630. 10.1177/147323000903700304.CrossRefPubMed
20.
go back to reference She JJ, Zhang PG, Wang ZM, Gan WM, Che XM: Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther. 2008, 7 (10): 1663-1668. 10.4161/cbt.7.10.6637.CrossRefPubMed She JJ, Zhang PG, Wang ZM, Gan WM, Che XM: Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther. 2008, 7 (10): 1663-1668. 10.4161/cbt.7.10.6637.CrossRefPubMed
21.
go back to reference Yang YM, Chang JW: Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008, 26 (7): 725-733. 10.1080/07357900801941845.CrossRefPubMed Yang YM, Chang JW: Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008, 26 (7): 725-733. 10.1080/07357900801941845.CrossRefPubMed
22.
go back to reference Dancik GM, Owens CR, Iczkowski KA, Theodorescu D: A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014, 32 (4): 974-982. 10.1002/stem.1625.CrossRefPubMedPubMedCentral Dancik GM, Owens CR, Iczkowski KA, Theodorescu D: A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014, 32 (4): 974-982. 10.1002/stem.1625.CrossRefPubMedPubMedCentral
23.
go back to reference Li Y, Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res. 2012, 72 (3): 576-580. 10.1158/0008-5472.CAN-11-3070.CrossRefPubMedPubMedCentral Li Y, Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res. 2012, 72 (3): 576-580. 10.1158/0008-5472.CAN-11-3070.CrossRefPubMedPubMedCentral
24.
go back to reference Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998, 22 (12): 1435-1448. 10.1097/00000478-199812000-00001.CrossRefPubMed Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998, 22 (12): 1435-1448. 10.1097/00000478-199812000-00001.CrossRefPubMed
25.
go back to reference Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, Viganò P, Brunelli S, Bossi M, Tredici G, Strada G, Dalprà L: Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci. 2010, 101 (2): 416-424. 10.1111/j.1349-7006.2009.01414.x.CrossRefPubMed Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, Viganò P, Brunelli S, Bossi M, Tredici G, Strada G, Dalprà L: Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci. 2010, 101 (2): 416-424. 10.1111/j.1349-7006.2009.01414.x.CrossRefPubMed
26.
go back to reference Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, Bacino CA, Pursley A, Li J, Erickson R, Gropman AL, Miller DT, Seashore MR, Summers AM, Stankiewicz P, Chinault AC, Lupski JR, Beaudet AL, Sutton VR: Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenetics. Am J Med Genet A. 2007, 143A (15): 1679-1686. 10.1002/ajmg.a.31740.CrossRefPubMed Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, Bacino CA, Pursley A, Li J, Erickson R, Gropman AL, Miller DT, Seashore MR, Summers AM, Stankiewicz P, Chinault AC, Lupski JR, Beaudet AL, Sutton VR: Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenetics. Am J Med Genet A. 2007, 143A (15): 1679-1686. 10.1002/ajmg.a.31740.CrossRefPubMed
27.
go back to reference Beissbarth T, Speed TP: GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004, 20 (9): 1464-1465. 10.1093/bioinformatics/bth088.CrossRefPubMed Beissbarth T, Speed TP: GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004, 20 (9): 1464-1465. 10.1093/bioinformatics/bth088.CrossRefPubMed
28.
go back to reference Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011, 144 (1): 27-40. 10.1016/j.cell.2010.11.055.CrossRefPubMedPubMedCentral Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011, 144 (1): 27-40. 10.1016/j.cell.2010.11.055.CrossRefPubMedPubMedCentral
29.
go back to reference Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W: Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology. 2010, 42 (4): 356-359. 10.3109/00313021003767298.CrossRefPubMed Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W: Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology. 2010, 42 (4): 356-359. 10.3109/00313021003767298.CrossRefPubMed
30.
go back to reference Panani AD, Roussos C: Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma. Anticancer Res. 2006, 26 (1A): 319-323.PubMed Panani AD, Roussos C: Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma. Anticancer Res. 2006, 26 (1A): 319-323.PubMed
31.
go back to reference Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2 (9): 533-543. 10.1016/S1470-2045(01)00486-7.CrossRefPubMed Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2 (9): 533-543. 10.1016/S1470-2045(01)00486-7.CrossRefPubMed
32.
go back to reference Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL: Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014, 111 (6): E672-81. 10.1073/pnas.1313580111.CrossRefPubMedPubMedCentral Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL: Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A. 2014, 111 (6): E672-81. 10.1073/pnas.1313580111.CrossRefPubMedPubMedCentral
33.
go back to reference Kinsella M, Patel A, Bafna V: The elusive evidence for chromothripsis. Nucleic Acids Res. 2014 Kinsella M, Patel A, Bafna V: The elusive evidence for chromothripsis. Nucleic Acids Res. 2014
34.
go back to reference Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi MG, Bovo G, Pallotti F, Viganò P, Strada G, Dalprà L, Bentivegna A: Chromosomal aberrations in bladder cancer: Fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS One. 2011, 6 (9): e24237-10.1371/journal.pone.0024237.CrossRefPubMedPubMedCentral Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi MG, Bovo G, Pallotti F, Viganò P, Strada G, Dalprà L, Bentivegna A: Chromosomal aberrations in bladder cancer: Fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS One. 2011, 6 (9): e24237-10.1371/journal.pone.0024237.CrossRefPubMedPubMedCentral
Metadata
Title
Chromosomal imbalances in human bladder urothelial carcinoma: similarities and differences between biopsy samples and cancer stem-like cells
Authors
Donatella Conconi
Elena Panzeri
Serena Redaelli
Giorgio Bovo
Paolo Viganò
Guido Strada
Leda Dalprà
Angela Bentivegna
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-646

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine